ArticleFrontiers in oncology2025
The value of spectral CT quantitative parameters in predicting Ki-67 level in ovarian cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of this study is to evaluate the predictive value of quantitative parameters from spectral CT for Ki-67 expression in ovarian cancer (OC). Methods: Spectral CT imaging data from 39 patients with ovarian cancer by pathology, encompassing 52 lesions overall, were collected retrospectively and split into two groups based on immunohistochemical results. Tumor solid components in arterial, venous, and delayed phases can be measured using post-processing software to obtain the quantitative parameters of spectral CT. An independent sample t-test was implemented for evaluating spectral CT parameters between two groups, and a Spearman correlation coefficient was applied among all participants to estimate the relationship between spectral parameters and Ki-67 levels. Moreover, an examination of the receiver operating characteristic (ROC) curve was conducted to assess the diagnostic efficacy of the significantly different parameters between the two groups. Results: The Ki-67 high-level group includes 22 patients and 29 lesions, while the Ki-67 low-level group contains 17 patients and 23 lesions. The A-sIC, A-sZeff, V-IC, D-Zeff, and D-sZeff values in the Ki-67 high-level group were greater than those in the Ki-67 low-level group ( Conclusion: Spectral CT provides multi-parametric imaging data and is useful in predicting Ki-67 expression in ovarian cancer, delivering comprehensive and reliable imaging evidence for the formulation of therapeutic treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.